Bambusa Therapeutics Presents Detailed BBT001 Atopic Dermatitis Proof-of-Concept Results at ISAD 2026
Detailed findings from a randomized, double-blind, placebo-controlled cohort presented by Eric Simpson, M.D., M.C.R., of Oregon Health & Science University Presentation brings previously announced clinical findings together with pharmacokinetic and biomarker evidence for scientific discussion Bambusa continues subcutaneous evaluation of BBT001 and preparations for Phase 2b development BOSTON, Oct.
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →